IMS studies use CoMMpass genomic data in multiple myeloma research

The CoMMpass genomic dataset for patients with multiple myeloma was used by researchers, contributing to 19 abstracts reported in the International Myeloma Society.

Data generated by the CoMMpass Longitudinal Genome Profiling Study (NCT01454297) has been used in several important clinical trials presented at the 19th Annual Meeting of the International Myeloma Society (IMS), according to a press release from the Multiple Myeloma Research Foundation (MMRF).1

CoMMpass, or Clinical Outcomes in the Genetic Profiling Multiple Myeloma Personal Assessment Trial, which collected data from an estimated 1,150 patients worldwide, provided data cited in 19 abstracts in IMS, including 4 oral presentations. It was also announced that the Multiple Myeloma Research Consortium presented results from the MyDRUG Clinical Trial (NCT03732703) that investigated precision medicine-targeted therapies in patients with multiple myeloma.

“Despite significant strides in treatment, multiple myeloma remains incurable and often fatal, which is why the use of the CoMMpass data, presented in 19 abstracts at the 19th IMS Annual Meeting, also underscores the value and utility of our comprehensive genomic and clinical data. Hearn Jay Chou, MD, PhD, chief medical officer of MMRF, said in a statement.

The CoMMpass study, which began collecting data in 2011, is the largest longitudinal genomic data set in patients with multiple myeloma and has provided valuable resources in the biology and genetics of the disease. Genomic profiles of patients from diagnosis of multiple myeloma onward through each treatment and relapse are monitored to investigate the relationship between patient genes and response to treatment.

Studies presented in IMS using CoMMpass include an analysis of a phase II CARDAMON trial (NCT02315716) that identified patients with wild-type MGAMAnd the CCDC168And the PDXDC1And the ABCC1 And the S1PR2 The genes had better responses to treatment with carfilzomib (Kyprolis) plus cyclophosphamide and dexamethasone, although these genes were not associated with motor mutations for multiple myeloma.2 CoMMpass patients with this gene signature who received carfilzomib had a median progression-free survival (PFS) of 58.8 months, whereas those without the gene signature had a median PFS of 33.2 months (s = .0067), confirming this correlation.

Another study identified an extramedullary disease-like transcription program caused by bone marrow stromal cells. Stromal interactions render multiple myeloma cells more resistant to the effects of cytotoxic therapy and immunotherapy.3 The CoMMpass MMRF IA16 cohort was one of 3 independent patient cohorts that were used to confirm the predictive significance of this finding in identifying patients with high-risk disease at risk for drug resistance and poor long-term survival.

Michael Andreni, CEO of MMRF, said in a statement.1

The MyDRUG Phase 1/2 study platform, which is guided by CoMMpass genetic data, is a comprehensive study designed to test targeted therapies used in other disease types, but not yet approved for patients with multiple myeloma, in high-risk patients who present genetically. modifications.

MyDRUG researchers present results of a subprotocol of patients with early relapsing multiple myeloma with mutations in NRASAnd the Brochureor BRAF.4 The investigators administered the MEK inhibitor cobimetinib (Cotellic) alone and then in combination with ixazomib (Ninlaro), pomalidomide (Pomalyst) and dexamethasone based on the efficacy of cobimetinib in melanoma patients with these mutations. With a median duration of treatment of 12 months, 6 out of 7 patients enrolled responded to treatment with 4 partial responses and very good partial responses. The mixture also appears to be safe.

Other research presented at IMS demonstrated the value of the CoMMpass dataset in validating study results and correlating patients’ genes with their treatment outcomes.

“The CoMMpass remains one of the most important drivers of myeloma research,” Chu said.1 “MMRF is committed to working closely with researchers around the world to achieve breakthroughs using CoMMpass data, with the goal of bringing us closer to accelerating treatment for every [patient with] Bone marrow.”

References:

1. The MMRF CoMMpass and MyDRUG studies are driving the discoveries in the research presented at the 19th IMS Annual Meeting. Multiple Myeloma Research Foundation. August 24, 2022. Accessed August 29, 2022. https://bit.ly/3pU1H4j

2. Walker I, Kandelwal J, Darcy V, et al. From CARDAMON to CoMMpass: a mutational signature that predicts carfilzomib-specific outcome in myeloma. Presented at: The 19th Annual Meeting of the International Myeloma Society. 25-27 August 2022; Los Angeles, California. Abstract OAB-018.

3. Binder M, Szalat R, Fulciniti M, et al. High-risk multiple myeloma due to extramedullary disease-like gene expression induced by bone marrow occlusive cells. Presented at: The 19th Annual Meeting of the International Myeloma Society. 25-27 August 2022; Los Angeles, California. Abstract OAB-021.

4. Kumar S, Jayasinghi R, Bianchi J, et al. Clinical and translational outcomes of myeloma development regimens using the C1 sub-protocol of genomics (MyDRUG) targeting RAS mutations. Presented at: The 19th Annual Meeting of the International Myeloma Society. 25-27 August 2022; Los Angeles, California. Abstract OAB-047.

Leave a Reply

Your email address will not be published.